Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Pseudomonas Stories

2009-07-30 07:36:00

MONMOUTH JUNCTION, N.J., July 30 /PRNewswire/ -- Transave Inc. announced today that it has entered into a cooperative research and development agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study ARIKACE(TM) (liposomal amikacin for inhalation) in patients with nontuberculous mycobacteria (NTM) lung infections. Transave and NIAID will collaborate on the planning, design and implementation of a clinical...

2009-07-23 07:00:00

MARKHAM, ON, July 23 /PRNewswire-FirstCall/ - AlphaRx, Inc. (OTCBB: ALRX) announced positive preclinical results which demonstrated that an inhaled tobramycin nanoparticle (Zysolin(TM)) formulation was a more effective treatment in animal models of acute Pseudomonas aeruginosa pneumonia when compared to inhaled and injected conventional tobramycin solutions. The data was presented recently in an oral podium session at the 36th Annual Meeting and Exposition of the Controlled Release Society in...

78a9537ad8af772662f43cdfb6bc51921
2009-07-10 10:20:00

Infections of wounds, pneumonia, etc. in hospitals in particular are often caused by bacteria called Pseudomonas aeruginosa. Once they reach a certain density, colonies of Pseudomonas aeruginosa produce virulence factors and can enter into a slimy state, a biofilm, which prevents antibiotics from penetrating. The process of quorum sensing, which cells use to "sense" cell density, is triggered when the concentration of certain signaling compounds generated by the bacteria reaches a threshold...

2009-06-30 06:00:00

SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa, including drug resistant isolates. Calixa is investigating CXA-101 as a potential treatment for serious bacterial infections in hospitalized patients. The...

2009-06-25 08:45:00

Company Also Receives Patent Covering ARIKACE for Once-Daily Treatment of Pseudomonas Lung Infections MONMOUTH JUNCTION, N.J., June 25 /PRNewswire/ -- Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, has provided a $2.2 million award to Transave Inc., for the continued development of ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat Pseudomonas lung infections in cystic fibrosis (CF) and non-CF...

2009-06-18 07:00:00

AlphaRx's inhaled Tobramycin nanoparticle formulation provides 300% more availability than standard free drug in lung tissue, as demonstrated in a recent animal pharmacokinetic study. MARKHAM, ON, June 18 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX) is pleased to report a significant breakthrough in the development of Zysolin(TM), an inhaled Tobramycin nanoparticle formulation utilizing the company's proprietary drug delivery platform, and intended for the adjunctive...

8e9363af5bedb0960deddb29e9995c221
2009-06-16 09:40:00

An international team of scientists has discovered extensive similarities between a strain of bacteria commonly associated with plants and one increasingly linked to opportunistic infections in hospital patients. The findings suggest caution in the use of the plant-associated strain for a range of biotech applications. The genetic analysis was conducted in part at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, and will be published in the July 2009 issue of Nature...

2009-06-11 11:48:43

Scottish and U.S. scientists say their discovery of how some bacteria protect themselves when they are under attack might lead to new antimicrobial drugs. The 25-year study -- led by University of Aberdeen Professor Ian Booth and researcher Tarmo Roosild of the Nevada Cancer Institute in Las Vegas -- determined the mechanics of channels in bacteria that stay shut if all is normal and are triggered to open if they need to mount a defense. The scientists said their finding could result in the...

2009-05-05 06:00:00

First Diagnostic Test for Identifying E. coli, K. pneumoniae and P. aeruginosa Directly from Positive Blood Cultures PNA FISH Provides Critical Results 24-48 Hours Sooner Than Conventional Methods to Help Clinicians Improve Care and Outcomes for 100,000 Patients with Gram-Negative Bloodstream Infections WOBURN, Mass., and VEDBAEK, Denmark, May 5 /PRNewswire/ -- AdvanDx today announced it received FDA 510(k) clearance for EK/P. aeruginosa PNA FISH(R) to identify Escherichia coli and/or K....

2009-04-25 10:54:51

Dartmouth Medical School researchers have devised a novel approach for thwarting the relentless bacterial infections that thrive in the lungs of people with cystic fibrosis (CF), unlocking new possibilities against a tenacious and toxic hallmark of the common genetic disease. Combining a mainstay antibiotic with drugs to deprive the bacteria of iron, which facilitates their persistent growth, appears to boost infection killing, they found. Their research, reported in the American Journal of...


Latest Pseudomonas Reference Libraries

0_85d9abd5d0844260722ff2e72fcc9f5a
2011-04-25 21:18:54

Pseudomonas aeruginosa is a common bacterium that can cause disease in animals and humans. It can be found in soil, water, skin flora, and most man-made environments throughout the world. It thrives in normal or hypoxic atmospheres; due to this it has colonized many natural and artificial environments. It can infect animals with damaged tissue or people with reduced immunity. Symptoms are generalized inflammation and sepsis. It can be fatal if colonization occurs in critical body organs,...

More Articles (1 articles) »